Scientists at the Institute of Cancer Research (ICR) in London have discovered that melanoma cells spread by harnessing a gene normally involved in the development of the nervous system.
Mount Sinai is leading a team of researchers that has been awarded a 3-year, USD 500,000 grant from Stand Up To Cancer (SU2C) to explore therapeutic approaches to lung tumors with mutations in the KRAS gene.
SELLAS Life Sciences has announced results from preclinical in vitro studies for its highly selective CDK9 inhibitor, GFH-009, in solid cancer and acute myeloid leukemia (AML) cell lines.
Investigators presented the development of a novel orthotopic xenograft mouse model to study the role of cancer-associated fibroblasts (CAFs) in tumor lymphangiogenesis and regional lymph node metastasis in lung cancer.
Chengdu Baiyu Pharmaceutical has presented pyrimidine derivatives acting as GTPase KRAS (Gly12Cys mutant) inhibitors reported to be useful for the treatment of cancer.
Monte Rosa Therapeutics has synthesized new proteolysis targeting chimera (PROTAC) compounds comprising a protein cereblon (CRBN) binding moiety covalently linked to a eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1)-targeting moiety reported to be useful for the treatment of cancer.
A University of Texas MD Anderson Cancer Center-based research team demonstrated that Col1 produced by pancreatic cancer cells is an oncogenic homotrimer variant (a1/a1/a1) instead of the normal Col1 heterotrimer (a1/a2/a1) produced by fibroblasts.
RSS